Side effects of PCSK9 inhibitors
Pro Research Analysisby 
Searched over 200M research papers
Common Side Effects of PCSK9 Inhibitors
PCSK9 inhibitors, such as alirocumab and evolocumab, are generally well tolerated, but some side effects have been reported. The most frequent side effects in real-world and clinical trial settings include injection-site reactions, which occur in about 33.8% of patients, and influenza-like symptoms, reported by 27.9% of patients. Myalgia (muscle pain) is also noted, with rates ranging from 8.3% to 12.8% in different databases. Most side effects are mild and resolve in the majority of patients, with only a small percentage (about 7%) discontinuing treatment due to adverse events Gürgöze2018Stoekenbroek2017Coppinger2022+1 MORE.
Serious Adverse Events and Discontinuation Rates
Serious adverse events (SAEs) are rare with PCSK9 inhibitors. Large meta-analyses and systematic reviews show no significant increase in the risk of serious adverse events, including myocardial infarction, stroke, heart failure, or all-cause death, compared to placebo. Discontinuation rates due to side effects are low, typically around 2.5% to 7% Gürgöze2018Bruggen2020Stoekenbroek2017+1 MORE.
Neurocognitive Side Effects and Safety
There has been concern about possible neurocognitive side effects, such as memory problems or confusion, with PCSK9 inhibitors. Most studies and meta-analyses have found no significant increase in neurocognitive adverse events compared to placebo. However, a few large outcome studies suggest a possible small increase in neurocognitive events, but the overall incidence remains less than 1%. Ongoing monitoring is recommended, but current evidence is reassuring Khan2017Hirsh-Raccah2020Karatasakis2017.
Muscle-Related and Metabolic Effects
Unlike statins, PCSK9 inhibitors rarely cause muscle-related side effects such as myopathy or elevated creatine kinase. The risk of new-onset or worsening diabetes is not significantly increased in clinical trials. However, genetic studies suggest that long-term use may be associated with a slightly higher risk of type 2 diabetes, increased body mass index, and central obesity, similar to what is seen with statins. These findings are not yet confirmed in long-term clinical studies Nelson2019Coppinger2022Karatasakis2017.
Kidney and Infection Risks
Recent pharmacovigilance studies indicate that PCSK9 inhibitors do not increase the risk of acute kidney injury (AKI); in fact, they may have a protective effect, even when used with other drugs that can affect the kidneys. Additionally, there is no evidence that PCSK9 inhibitors increase the risk of sepsis or severe infections, providing further reassurance about their safety profile Liu2024Zhou2023.
Conclusion
PCSK9 inhibitors are generally safe and well tolerated, with the most common side effects being mild injection-site reactions, flu-like symptoms, and occasional muscle pain. Serious adverse events are rare, and there is no significant increase in neurocognitive, kidney, or infection risks. While genetic data suggest a possible small increase in diabetes risk with long-term use, this has not been clearly seen in clinical trials. Overall, PCSK9 inhibitors offer a favorable safety profile for patients needing additional cholesterol lowering.
Sources and full results
Most relevant research papers on this topic